October 2, 2022

Medical Trend

Medical News and Medical Resources

Chinese COVID-19 Vaccines Transport at 2-8°C

Chinese COVID-19 Vaccines Transport at 2-8°C

Chinese COVID-19 Vaccines Transport at 2-8°C.  The releasing schedule of 600 million inactivated vaccines have been confirmed

600 million inactivated vaccines have been released

According to the Yangtze River Daily, today (December 4), when Wang Junzhi, deputy leader of the Vaccine R&D Expert Team of the Scientific Research Group and academician of the Chinese Academy of Engineering, delivered a speech on “COVID-19 Pneumonia Vaccine and Drug R&D Progress” at the Eighth World Congress of Integrated Traditional Chinese and Western Medicine Said, “Regarding vaccines, there will be big news in the next one to two weeks.” “600 million inactivated vaccines will be approved for the market within this year.”

The safety of the vaccine is controllable and can be transported at 2-8 degrees Celsius

According to a report from the Wuhan Evening News, Wang Junzhi introduced that as early as the beginning of the epidemic, the scientific research team deployed vaccine tasks as soon as possible, and successively deployed inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines and Five technical routes of nucleic acid vaccines were developed in parallel, and 12 nationally superior teams were organized to conduct joint research.

According to Wang Junzhi, as of December 2, there are 214 vaccines under development worldwide. Of these, 51 have entered clinical studies (14 in China), and 14 have entered phase III clinical trials (6 in China). Of the 6 vaccines that have entered Phase III clinical trials in China, 4 of them are inactivated vaccines.

“This in itself is the result of Chinese accumulated research and development capabilities, technology and experience in the field of vaccines over the years, reflecting some countries’s relatively good technical and institutional advantages in vaccine research and development.” Wang Junzhi said that for inactivated vaccines, in some countries It is relatively mature and has better technology.

Not only that, the main features of inactivated vaccines are the closest to the natural virus structure, so the human body’s immune response after application is relatively strong, and the safety is controllable. In addition, it is relatively stable and can be transported at 2-8 degrees Celsius, and cold chain transportation is very convenient.

“The entire R&D, production, quality control, safety and effectiveness evaluation standards of inactivated vaccines are relatively mature. We have rich experience and adopt advanced purification and quality control technologies to achieve antigen purity of more than 95%. The recombinant protein vaccine has the same standards.” Wang Junzhi said that after the inactivated vaccine is prepared, after multiple phases of clinical trials, it has initially obtained good safety and immunogenicity results.

Sun Chunlan: Prepare for mass production

Earlier, according to Xinhua News Agency, Chinese Vice Premier Sun Chunlan and State Councilor Wang Yong were in Beijing on December 2 to investigate the preparations for the development and production of new coronavirus vaccines, and on-site visits to China Food and Drug Control Institute, Beijing Kexing Company, and Sinopharm Zhongsheng The Beijing company has an in-depth understanding of the new coronavirus vaccine scientific research, production workshop construction, and preparation for batch issuance, and fully affirmed the achievements of the vaccine work.

Sun Chunlan pointed out that in the next step, we must continue to advance the vaccine phase III clinical trials scientifically and rigorously, and conduct review and approval in strict accordance with laws, regulations and internationally recognized technical standards to ensure that the vaccine is safe, effective, and can withstand all aspects of inspection.

We must be prepared for large-scale production, in strict accordance with laws, procedures and requirements such as quality supervision and biosafety, improve the traceability system of the entire vaccine process, severely punish violations of laws and regulations in accordance with the law, and create a good market environment. It is necessary to study and formulate the vaccination distribution plan after the vaccine is on the market, clarify the population range, vaccination sequence and time considerations, and organize the training of personnel of disease control agencies and grassroots vaccination units in advance.

According to the needs of winter epidemic prevention and control, emergency use of high-risk groups such as port-related employees and front-line supervisors will be completed this year.

Vaccines are related to people’s life safety. All relevant departments must strictly enforce management systems for vaccine research and development, production, circulation, and use, strengthen batch issuance and supervision capacity building, help R&D units and manufacturers solve practical problems, and carry out publicity and education of vaccine knowledge, The people have a scientific and rational understanding of vaccines, and actively carry out preventive vaccination and personal protection.